C/EBPβ expression in ALK-positiveanaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway

Haematologica

Volumn 95, Issue 5, 2010, Pages 760-767

  Anastasov, Natasa ^a   Bonzheim, Irina ^b   Rudelius, Martina ^c   Klier, Margit ^b   Dau, Therese ^a   Angermeier, Daniela ^a,c   Duyster, Justus ^c   Pittaluga, Stefania ^d   Fend, Falko ^b   Raffeld, Mark ^d   Quintanilla Martinez, Leticia ^a,b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anaplastic large cell lymphoma (ALCL); C EBP ; Cell proliferation; RNA interference; STAT3

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CCAAT ENHANCER BINDING PROTEIN BETA; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 3; SHORT HAIRPIN RNA; STAT3 PROTEIN; THREONINE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GENE SILENCING; GROWTH RETARDATION; LARGE CELL LYMPHOMA; NONHUMAN; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; RNA SEQUENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANIMALS; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL LINE; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MICE; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 77952310507     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.014050     Document Type: Article

References (34)

1. Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene. 1997;14(4):439-49.
2. Duyster J, Bai RY, Morris SW. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene. 2001; 20(10): 5623-37.
3. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008; 8(1):11-23.
4. Bai RY, Dieter P, Peschel C, Morris SW, Duyster J. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lym- phoma is a constitutively active tyrosine kinase that utilizes phospholipase C-γ to mediate its mitogenicity. Mol Cell Biol. 1998; 18(12):6951-61.
5. Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J. Nucliophosmin- anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma acti- vates the phosphatidylinositol 3- kinase/Akt antiapoptotic signaling path-way. Blood. 2000; 96(13):4319-27.
6. Quintanilla-Martinez L, Pittaluga S, Miething C, Klier M, Rudelius M, Davies-Hill T, et al. NPM-ALK-dependent expres-sion of the transcription factor CCAAT/enhancer binding protein β in ALK-positive anaplastic large cell lym-phoma. Blood. 2006;108(6): 2029-36.
7. Lamant L, de Reynies A, Duplantier MM, Rickman DS, Sabourdy F, Giuriato S, et al. Gene-expression profiling of systemic anaplastic largecell lymphoma reveals differences based on ALK status and two dis-tinct morphologic ALK+ subtypes. Blood. 2007;109(5):2156-64.
8. Piva R, Pellegrino E, Mattioli M, Agnelli L, Lombardi L, Boccalatte F, et al. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest. 2006;116(12):3171-82.
9. Nerlov C. C/EBPa mutations in acute myeloid leukemias. Nature Reviews Cancer. 2004;4(5):394-400.
10. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravulu S, Schnittger S, et al. Dominant negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-a (C/EBPa), in acute myeloid leukemia. Nat Genet. 2001;27(3):263-70.
11. Tenen DG. Disruption of differentiation in human cancer: AML shows the way. Nature Reviews Cancer. 2003;3(2):89-101.
12. Descombes P, Schibler U. A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. Cell. 1991;67(3):569-79.
13. Goransson M, Elias E, Stahlberg A, Olofsson A, Andersson C, Aman P. Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression. Int J Cancer. 2005;115(4):556-60.
14. Gao LF, Xu DQ, Wen LJ, Zhang XY, Shao YT, Zhao XJ. Inhibition of STAT3 expression by siRNA suppresses growth and induces apoptosis in laryngeal cancer cells. Acta Pharmacol Sin. 2005;26(3):377-83.
15. Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res. 2006;66(13):6589-97.
16. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002;296(5567):550-3.
17. Anastasov N, Klier M, Koch I, Angermeier D, Hoefler H, Fend F, et al. Efficient shRNA delivery into B and T lymphoma cells using lentiviral vector-mediated transfer. J Hematopathol. 2009;2(1):9-19.
18. Klier M, Anastasov N, Hermann A, Meindl T, Angermeier D, Raffeld M, et al. Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2. Leukemia. 2008;22(11):2097-105.
19. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science. 2002;295(5556):868-72.
20. Specht K, Kremer M, Muller U, Dirnhofer S, Rosemann M, Hofler H, et al. Identification of cyclin D1 mRNA overex- pression in B-cell neoplasias by real-time reverse transcription-PCR of microdissect- ed paraffin sections. Clin Cancer Res. 2002; 8(9):2902-11.
21. Sundfeldt K, Ivarsson K, Carlsson M, Enerback S, Janson PO, Brannstrom M, et al. The expression of CCAAT/enhancer binding protein (C/EBP) in the human ovary in vivo: specific increase in C/EBPbeta during epithelial tumour progression. Br J Cancer. 1999;79(7-8):1240-8.
22. Rask K, Thorn M, Ponten F, Kraaz W, Sundfeldt K, Hedin L, et al. Increased expression of the transcription factors CCAAT-enhancer binding protein-beta (C/EBBeta) and C/EBzeta (CHOP) correlate with invasiveness of human colorectal cancer. Int J Cancer. 2000;86(3):337-43.
23. Eaton EM, Hanlon M, Bundy L, Sealy L. Characterization of C/EBPbeta isoforms in normal versus neoplastic mammary epithelial cells. J Cell Physiol. 2001;189(1): 91-105.
24. Niehof M, Streetz K, Rakemann T, Bischoff SC, Manns MP, Horn F, et al. Interleukin-6- induced tethering of Stat3 to the LAP/C/EBPβ promter suggests a new mechanism of transcriptional regulation by Stat3. J Biol Chem. 2001;276(12):9016-27.
25. Niemand C, Nimmesgern A, Haan S, Fischer P, Schaper F, Rossaint R, et al. Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J Immunol. 2003;170(6):3263-72.
26. Tanaka N, Hoshino Y, Gold J, Hoshino S, Martiniuk F, Kurata T, et al. Interleukin-10 induces inhibitory C/EBPbeta through STAT-3 and represses HIV-1 transcription in macrophages. Am J Respir Cell Mol Biol. 2005;33(4):406-11.
27. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med. 2005;11(6):623-9.
28. Piwien-Pilipuk G, Van Mater D, Ross SE, MacDougald OA, Schwartz J. Growth hormone regulates phosphorylation and function of CCAAT/enhancer-binding protein beta by modulating Akt and glycogen synthase kinase-3. J Biol Chem. 2001; 276(22):19664-71.
29. Piwien-Pilipuk G, MacDougald O, Schwartz J. Dual regulation of phosphorylation and dephosphorylation of C/EBPbeta modulate its transcriptional activation and DNA binding in response to growth hormone. J Biol Chem. 2002; 277(46):44557-65.
30. Piwien Pilipuk G, Galigniana MD, Schwartz J. Subnuclear localization of C/EBP beta is regulated by growth hormone and dependent on MAPK. J Biol Chem. 2003;278(37):35668-77.
31. Marzec M, Kasprzycka M, Liu X, Raghunath PN, Wlodarski P, Wasik MA. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf. Oncogene. 2007;26(6):813-21.
32. Marzec M, Kasprzycka M, Liu X, El-Salem M, Halasa K, Raghunath PN, et al. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Oncogene. 2007;26(38):5606-14.
33. Jundt F, Raetzel N, Muller C, Calkhoven CF, Kley K, Mathas S, et al. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein β and NF-kB activity in Hodgkin and anaplastic large cell lymphomas. Blood. 2005;106(5):1801-7.
34. Calkhoven CF, Muller C, Leutz A. Translational control of gene expression and disease. Trends Mol Med. 2002;8(12): 577-83.